List of Mulpleta drug patents
Mulpleta is owned by Shionogi Inc.
Mulpleta contains Lusutrombopag.
Mulpleta has a total of 4 drug patents out of which 0 drug patents have expired.
Mulpleta was authorised for market use on 31 July, 2018.
Mulpleta is available in tablet;oral dosage forms.
Mulpleta can be used as treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Drug patent challenges can be filed against Mulpleta from 2022-07-31.
The generics of Mulpleta are possible to be released after 29 September, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7601746 | SHIONOGI INC | Compounds exhibiting thrombopoietin receptor agonism |
Sep, 2024
(1 year, 5 months from now) | |
| US8889722 | SHIONOGI INC | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jul, 2028
(5 years from now) | |
| US8530668 | SHIONOGI INC | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jan, 2030
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427402 | SHIONOGI INC | Preparation for improving solubility of poorly soluble drug |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 2022-07-31
Market Authorisation Date: 31 July, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Dosage: TABLET;ORAL
MULPLETA family patents
11
Japan
8
China
6
United States
3
Taiwan, Province of China
3
Korea, Republic of
3
Canada
3
European Union
2
Russia
2
Spain
2
Brazil
2
Australia
1
Portugal
1
Croatia
1
Mexico
1
Cyprus
1
Slovenia
1
Poland
1
Denmark
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic